Cancer preceding Wegener's granulomatosis: A case-control study

Rheumatology

Volumn 48, Issue 4, 2009, Pages 421-424

  Faurschou, Mikkel ^a   Mellemkjaer, Lene ^b   Sorensen, Inge J ^c   Thomsen, Bjarne S ^d   Dreyer, Lene ^a   Baslund, Bo ^a  

^a Rigshospitalet   (Denmark)

^b INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cancer; Case control study; Malignancy; Non melanoma skin cancer; Vasculitis; Wegener's granulomatosis

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SKIN CANCER; TESTIS CANCER; TRANSITIONAL CELL CARCINOMA; VASCULITIS; WEGENER GRANULOMATOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DENMARK; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; PREVALENCE; RISK; SKIN NEOPLASMS; TESTICULAR NEOPLASMS; VASCULITIS; WEGENER GRANULOMATOSIS; YOUNG ADULT;

EID: 63249106028     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep009     Document Type: Article

References (24)

1. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33:1101-7.
2. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 1992;116:488-98.
3. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37: 187-92.
4. Watts R, Lane S, Hanslik T et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and poly-arteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-7.
5. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85.
6. Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener's granulomatosis. Curr Opin Rheumatol 2006;18:25-32.
7. Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: Initiatives of the European community systemic vasculitis clinical trials study group. Mayo Clin Proc 1997;72:737-47.
8. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
9. Faurschou M, Sorensen IJ, Mellemkjaer L et al. Malignancies in Wegener's granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008;35:100-5.
10. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002;100:82-5.
11. Talar-Williams C, Hijazi YM, Walther MM et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477-84.
12. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842-52.
13. Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: Risks and relation to cyclophosphamide. Ann Rheum Dis 2004;63:1307-11.
14. Tatsis E, Reinhold-Keller E, Steindorf K, Feller AC, Gross WL. Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum 1999;42:751-6.
15. Pankhurst T, Savage CO, Gordon C, Harper L. Malignancy is increased in ANCA-associated vasculitis. Rheumatology 2004;43:1532-5.
16. Hellmich B, Kausch I, Doehn C, Jocham D, Holl-Ulrich K, Gross WL. Urinary bladder cancer in Wegener's granulomatosis: Is it more than cyclophosphamide? Ann Rheum Dis 2004;63:1183-5.
17. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 1997;44:535-9.
18. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-8.
19. Cancer Incidence in Denmark 1996. Copenhagen: Danish National Board of Health, 1999.
20. International Classification of Diseases for Oncology (ICD-O), 1st edition. Geneva: World Health Organization, 1976.
21. Breslow NE, Day NE. Statistical methods in cancer research. The analysis of case-control studies, Vol. 1. Lyon: International Agency for Research on Cancer 1980;(IARC Scientific Publications No. 32).
22. Bouwes Bavinck JN, Hardie DR, Green A et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996;61:715-21.
23. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000;143:513-9.
24. Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006;154:498-504.